1. A novel androstenedione derivative induces ROS-mediated autophagy and attenuates drug resistance in osteosarcoma by inhibiting macrophage migration inhibitory factor (MIF).
- Author
-
Liu Y, Zhao L, Ju Y, Li W, Zhang M, Jiao Y, Zhang J, Wang S, Wang Y, Zhao M, Zhang B, and Zhao Y
- Subjects
- Acetylcysteine pharmacology, Adenine analogs & derivatives, Adenine pharmacology, Androstenedione analogs & derivatives, Androstenedione chemical synthesis, Bone Neoplasms metabolism, Bone Neoplasms pathology, Cell Line, Tumor, Down-Regulation drug effects, Drug Resistance, Neoplasm drug effects, Gene Expression Regulation, Neoplastic drug effects, HMGB1 Protein metabolism, Humans, Macrophage Migration-Inhibitory Factors antagonists & inhibitors, Macrophage Migration-Inhibitory Factors genetics, Osteosarcoma metabolism, Osteosarcoma pathology, Proto-Oncogene Proteins c-bcl-2 metabolism, RNA Interference, RNA, Small Interfering metabolism, Reactive Oxygen Species metabolism, Secosteroids chemical synthesis, Secosteroids chemistry, Translocation, Genetic, Androstenedione toxicity, Autophagy drug effects, Macrophage Migration-Inhibitory Factors metabolism, Secosteroids toxicity
- Abstract
Osteosarcoma is a common primary bone tumor in children and adolescents. The drug resistance of osteosarcoma leads to high lethality. Macrophage migration inhibitory factor (MIF) is an inflammation-related cytokine implicated in the chemoresistance of breast cancer. In this study, we isolated a novel androstenedione derivative identified as 3,4-dihydroxy-9,10-secoandrosta-1,3,5,7-tetraene-9,17-dione (DSTD). DSTD could inhibit MIF expression in MG-63 and U2OS cells. The inhibition of MIF by DSTD promoted autophagy by inducing Bcl-2 downregulation and the translocation of HMGB1. N-acetyl-L-cysteine (NAC) and 3-methyladenine (3-MA) attenuated DSTD-induced autophagy but promoted cell death, suggesting that DSTD induced ROS-mediated autophagy to rescue cell death. However, in the presence of chemotherapy drugs, DSTD enhanced the chemosensitivity by decreasing the HMGB1 level. Our data suggest MIF inhibition as a therapeutic strategy for overcoming drug resistance in osteosarcoma.
- Published
- 2014
- Full Text
- View/download PDF